MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12672-025-03841-0

Медицинская библиотека · Discover oncology · 2025

Pan-cancer multi-omics analysis reveals IQCE as a malignant cell-restricted oncogenic biomarker driving immunosuppression and chemoresistance in cutaneous melanoma.

Luo Qing, Wang Jingya, Chen Ting, Li Jielong

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Cutaneous melanoma (SKCM) presents significant therapeutic challenges due to heterogeneity and acquired resistance to targeted and immune checkpoint blockade therapies. IQCE, a ciliary scaffold protein, has poorly defined roles in cancer. Its clinical significance, molecular mechanisms, and impact on the tumor microenvironment (TME) and therapy response are largely unknown.

METHODS

We conducted a comprehensive pan-cancer multi-omics analysis of IQCE using genomic, transcriptomic, proteomic, spatial transcriptomic, single-cell transcriptomic, and pharmacogenomic datasets. Analyses included differential expression, survival, pathway enrichment, immune deconvolution, cellular localization, and drug sensitivity prediction.

RESULTS

IQCE was significantly upregulated in multiple solid tumors, most notably cutaneous melanoma (SKCM), liver hepatocellular carcinoma (LIHC), and glioblastoma (GBM), demonstrating strong diagnostic value. High IQCE independently predicted poor prognosis in SKCM. Mechanistically, elevated IQCE correlated with suppression of immune pathways (e.g., cytokine signaling), inhibition of apoptosis, and activation of RAS/MAPK/RTK oncogenic signaling. Single-cell and spatial analyses confirmed IQCE enrichment specifically within malignant cells. High IQCE was associated with broad chemoresistance. Pharmacogenomic profiling revealed a consistent inverse correlation between IQCE expression and sensitivity to the p53-reactivating compound RITA.

CONCLUSION

IQCE emerges as a novel oncogene-associated biomarker with significant diagnostic and prognostic utility, particularly in SKCM. It promotes an immunosuppressive TME and oncogenic signaling while being localized to malignant cells. Although associated with chemoresistance, the vulnerability of IQCE-high tumors to RITA offers a promising therapeutic strategy. IQCE represents a compelling target for precision oncology.

Для цитирования: Luo Qing, Wang Jingya, Chen Ting, Li Jielong. Pan-cancer multi-omics analysis reveals IQCE as a malignant cell-restricted oncogenic biomarker driving immunosuppression and chemoresistance in cutaneous melanoma.. Discover oncology. 2025. DOI: 10.1007/s12672-025-03841-0.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.